nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adjuvant chemotherapy in elderly women with breast cancer (AChEW): an observational study identifying MDT perceptions and barriers to decision making
|
Ring, A. |
|
|
24 |
5 |
p. 1211-1219 |
artikel |
2 |
AIB1 and its significant role in tumor pathogenesis in systemic malignancies: beyond breast carcinomas
|
Kapoor, S. |
|
|
24 |
5 |
p. 1414 |
artikel |
3 |
A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors
|
Vermorken, J.B. |
|
|
24 |
5 |
p. 1392-1400 |
artikel |
4 |
Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort
|
Cheedella, N.K.S. |
|
|
24 |
5 |
p. 1262-1266 |
artikel |
5 |
Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer
|
Vera-Badillo, F.E. |
|
|
24 |
5 |
p. 1238-1244 |
artikel |
6 |
Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database
|
Olszewski, A.J. |
|
|
24 |
5 |
p. 1352-1359 |
artikel |
7 |
Critical review of ‘Public domain application’: a flexible drug approval system in Japan
|
Ito, Y. |
|
|
24 |
5 |
p. 1297-1305 |
artikel |
8 |
Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
|
Vehreschild, M.J.G.T. |
|
|
24 |
5 |
p. 1189-1202 |
artikel |
9 |
Docetaxel–cisplatin might be superior to docetaxel–capecitabine in the first-line treatment of metastatic triple-negative breast cancer †
|
Fan, Y. |
|
|
24 |
5 |
p. 1219-1225 |
artikel |
10 |
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
|
Holte, H. |
|
|
24 |
5 |
p. 1385-1392 |
artikel |
11 |
Editorial board
|
|
|
|
24 |
5 |
p. ii-iii |
artikel |
12 |
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial
|
Okines, A.F.C. |
|
|
24 |
5 |
p. 1253-1261 |
artikel |
13 |
Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
|
Tougeron, D. |
|
|
24 |
5 |
p. 1267-1273 |
artikel |
14 |
Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study
|
Yoshioka, H. |
|
|
24 |
5 |
p. 1326-1331 |
artikel |
15 |
Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer
|
Lee, J.S. |
|
|
24 |
5 |
p. 1225-1231 |
artikel |
16 |
Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications
|
Kuykendal, A.R. |
|
|
24 |
5 |
p. 1338-1343 |
artikel |
17 |
How to assess assessments?
|
Tenhunen, O. |
|
|
24 |
5 |
p. 1138-1140 |
artikel |
18 |
Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy
|
Wang, H.M. |
|
|
24 |
5 |
p. 1312-1319 |
artikel |
19 |
Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH
|
Mian, M. |
|
|
24 |
5 |
p. 1378-1384 |
artikel |
20 |
Light drinking has positive public health consequences
|
Steichen, O. |
|
|
24 |
5 |
p. 1420-1421 |
artikel |
21 |
Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study
|
Wirth, A. |
|
|
24 |
5 |
p. 1344-1351 |
artikel |
22 |
Management of the axilla in early breast cancer patients in the genomic era
|
Oliveira, M. |
|
|
24 |
5 |
p. 1163-1170 |
artikel |
23 |
Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series
|
Merok, M.A. |
|
|
24 |
5 |
p. 1274-1282 |
artikel |
24 |
Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective
|
Cortinovis, D. |
|
|
24 |
5 |
p. 1418-1419 |
artikel |
25 |
NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia
|
Terwey, T.H. |
|
|
24 |
5 |
p. 1363-1370 |
artikel |
26 |
Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages
|
Zhou, J.X. |
|
|
24 |
5 |
p. 1319-1325 |
artikel |
27 |
Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial †
|
Oakman, C. |
|
|
24 |
5 |
p. 1203-1211 |
artikel |
28 |
Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?
|
Pusceddu, S. |
|
|
24 |
5 |
p. 1415-1416 |
artikel |
29 |
Patients’ and physicians’ roles in detecting recurrent Hodgkin lymphoma following complete remission †
|
Bestawros, A. |
|
|
24 |
5 |
p. 1359-1363 |
artikel |
30 |
Penile cancer: current therapy and future directions
|
Sonpavde, G. |
|
|
24 |
5 |
p. 1179-1189 |
artikel |
31 |
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
|
Sandhu, S.K. |
|
|
24 |
5 |
p. 1416-1418 |
artikel |
32 |
Prostate cancer: ESMO Consensus Conference Guidelines 2012
|
Horwich, A. |
|
|
24 |
5 |
p. 1141-1162 |
artikel |
33 |
Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
|
Zielinski, C. |
|
|
24 |
5 |
p. 1170-1179 |
artikel |
34 |
Regarding the letter to the editor ‘AIB1 and its significant role in tumor pathogenesis in systemic malignancies: beyond breast carcinomas’ by Kapoor and Shailendra in Annals of Oncology
|
Alkner, S. |
|
|
24 |
5 |
p. 1414-1415 |
artikel |
35 |
Regular recreational physical activity and risk of hematologic malignancies: results from the prospective VITamins And lifestyle (VITAL) study †
|
Walter, R.B. |
|
|
24 |
5 |
p. 1370-1377 |
artikel |
36 |
Relevance of a systematic geriatric screening and assessment in older patients with cancer: results of a prospective multicentric study
|
Kenis, C. |
|
|
24 |
5 |
p. 1306-1312 |
artikel |
37 |
Re: light drinking has positive public health consequences
|
Bagnardi, V. |
|
|
24 |
5 |
p. 1421-1422 |
artikel |
38 |
Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread—results of a large prospective trial
|
Andreou, D. |
|
|
24 |
5 |
p. 1400-1405 |
artikel |
39 |
Table of Contents
|
|
|
|
24 |
5 |
p. iv-vi |
artikel |
40 |
The identification of predictive factors for perioperative chemotherapy in esophago-gastric cancer
|
Lordick, F. |
|
|
24 |
5 |
p. 1135-1138 |
artikel |
41 |
The role of AIB1 and PAX2 in primary breast cancer: validation of AIB1 as a negative prognostic factor
|
Alkner, S. |
|
|
24 |
5 |
p. 1244-1252 |
artikel |
42 |
The significance of the HER-2 status in esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybridization study †
|
Prins, M.J.D. |
|
|
24 |
5 |
p. 1290-1297 |
artikel |
43 |
Treatment of testicular intraepithelial neoplasia (intratubular germ cell neoplasia unspecified) with local radiotherapy or with platinum-based chemotherapy: A survey of the German Testicular Cancer Study Group
|
Dieckmann, K.-P. |
|
|
24 |
5 |
p. 1332-1337 |
artikel |
44 |
Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma
|
Calafiore, L. |
|
|
24 |
5 |
p. 1406-1413 |
artikel |
45 |
Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer
|
Ligthart, S.T. |
|
|
24 |
5 |
p. 1231-1238 |
artikel |
46 |
VEGFR-2, CXCR-2 and PAR-1 germline polymorphisms as predictors of survival in pancreatic carcinoma
|
Uzunoglu, F.G. |
|
|
24 |
5 |
p. 1282-1290 |
artikel |
47 |
What do European community oncologists expect from the European Society for Medical Oncology? Results from a survey among community oncologists in Germany, Greece, Hungary, Italy, Luxembourg, Romania, and Spain
|
Eckert, R. |
|
|
24 |
5 |
p. 1419-1420 |
artikel |